AMG-119

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAMG-119

Drug Alias NameAMG-119

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionDelta-like protein 3 inhibitors

TargetsDelta-like protein 3

Therapy Area/IndicationsSmall Cell Lung Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAmgen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAmgen Inc

Active IndicationsN/A

Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A